Skip to main content
SpringerLink
Log in

Lupus nephritis and Raynaud’s phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This study is aimed to determine the predictors of nongravid vascular thrombosis in systemic lupus erythematosus (SLE) patients with positive antiphospholipid antibodies (SLE-aPL). A cohort of 67 SLE-aPL patients who had at least one positive test for lupus anticoagulant (LA), anticardiolipin (aCL), or anti-beta2glycoprotein-1(B2) was examined. Main outcome was the presence of vascular thrombosis. Association between thrombosis and risk factors was examined by contingency table. The odds ratio (OR) of significant predictors was determined by logistic regression. Three percent of patients were LA+, 6% were aCL+, 31% were B2+, 3% were aCL+LA+, 35.8% were aCL+B2+, 7.5% were LA+B2+, and 13.4% were positive for all tests. As for clinical manifestations, 79% had lymphopenia, 76% had lupus nephritis (LN), 41.8% had autoimmune hemolytic anemia, 34.3% had thrombocytopenia, 20.9% had abortion, and 19.4% had Raynaud’s phenomenon (RP). Thrombosis occurred in 26 patients. The prevalence of thrombosis for SLE-aPL was 38.8%. Thrombosis was observed more frequently in patients with LA+ (12 of 18) than the others (14 of 49; p = 0.01). Two-by-two table showed that oral contraceptive and LN were significantly associated with increased risk of thrombosis, while lymphopenia and antimalarials were significantly associated with decreased risk of thrombosis. Multivariate analysis confirmed that LN and RP were associated with increased risk of thrombosis (OR = 6.2 and 3.2; p = 0.005 and 0.008), while lymphopenia and antimalarials were associated with decreased risk of thrombosis (OR = 0.86 and 0.18; p = 0.02 and 0.034). LA is the strongest test to determine the risk of thrombosis in SLE-aPL. The presence of LN and RP strongly predicts thrombosis, while lymphopenia and antimalarials are protective. These findings help to identify patients who may benefit from prophylactic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Viana JL, Haga HJ, Tripathi P, Cervera R, Khamashta MA, Hughes GR (1992) Reassessing the status of antiphospholipid síndrome in systemic lupus erythematosus. Ann Rheum Dis 51:160–161

    Article  Google Scholar 

  2. Love PE, Santoro SA (1990) Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 112:682–698

    PubMed  CAS  Google Scholar 

  3. Drenkard C, Villa AR, Alarcon-Segovia D, Perez-Vazquez ME (1994) Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 21:1067–1072

    PubMed  CAS  Google Scholar 

  4. Alarcon-Segovia D, Perez-Vazquez ME, Villa AR, Drenkard C, Cabiedes J (1992) Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 21:275–286

    Article  PubMed  CAS  Google Scholar 

  5. Somers E, Magder LS, Petri M (2002) Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with SLE. J Rheumatol 29:2531–2536

    PubMed  CAS  Google Scholar 

  6. Viard JP, Amoura Z, Bach JF (1992) Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 93:181–186

    Article  PubMed  CAS  Google Scholar 

  7. Galli M, Luciani D, Bertolini G, Barbui T (2003) Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102:2717–2723

    Article  PubMed  CAS  Google Scholar 

  8. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725

    Article  PubMed  CAS  Google Scholar 

  9. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299–308

    Article  Google Scholar 

  10. Petri M, Spence D, Bone LR, Hochberg MC (1992) Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 71:291–302

    CAS  Google Scholar 

  11. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R et al (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44:2331–2337

    Article  PubMed  CAS  Google Scholar 

  12. Toloza SM, Uribe AG, McGwin G Jr, Alarcon GS, Fessler BJ, Bastian HM et al (2004) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 50:3947–3957

    Article  PubMed  Google Scholar 

  13. Oger E (2000) Incidence of venous thromboembolism: a community-based study in western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 83:657–660

    PubMed  CAS  Google Scholar 

  14. White RH, Zhou H, Romano PS (1998) Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 128:737–740

    PubMed  CAS  Google Scholar 

  15. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA et al (2001) Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80:355–377

    Article  CAS  Google Scholar 

  16. Erkan D, Cervera R, Asherson RA (2003) Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum 48:3320–3327

    Article  PubMed  Google Scholar 

  17. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87:518–522

    PubMed  CAS  Google Scholar 

  18. Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN (1997) Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96:4380–4384

    PubMed  CAS  Google Scholar 

  19. Petri M, Lakatta C, Magder L, Goldman D (1994) Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 96:254–259

    Article  PubMed  CAS  Google Scholar 

  20. Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G et al (2004) Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 43:28–36

    Article  PubMed  CAS  Google Scholar 

  21. Alarcon-Segovia D, Boffa MC, Branch W, Cervera R, Gharavi A, Khamashta M et al (2003) Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 12:499–503

    Article  PubMed  CAS  Google Scholar 

  22. Petri M (1996) Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 25:191–193

    Article  PubMed  CAS  Google Scholar 

  23. Fischer K, Collins H, Taniguchi M, Kaufmann SH, Schaible UE (2002) IL-4 and T cells are required for the generation of IgG1 isotype antibodies against cardiolipin. J Immunol 168:2689–2694

    PubMed  CAS  Google Scholar 

  24. Frampton G, Hicks J, Cameron JS (1991) Significance of anti-phospholipid antibodies in patients with lupus nephritis. Kidney Int 39:1225–1231

    Article  PubMed  CAS  Google Scholar 

  25. Calvo-Alen J, Toloza SM, Fernandez M, Bastian HM, Fessler BJ, Roseman JM et al (2005) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 52:2060–2068

    Article  PubMed  CAS  Google Scholar 

  26. Nojima J, Iwatani Y, Suehisa E, Kuratsune H, Kanakura Y (2006) The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica 91:699–702

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Allergy–Immunology–Rheumatology, Department of Medicine, Ramathibodi Hospital, 270 Rama6 Road, Bangkok, 10400, Thailand

    Kittiwan Choojitarom, Orawan Verasertniyom, Kitti Totemchokchyakarn, Kanokrat Nantiruj & Suchela Janwityanujit

  2. Division of Nephrology, Department of Medicine, Ramathibodi Hospital, 270 Rama6 Road, Bangkok, 10400, Thailand

    Vasant Sumethkul

Authors
  1. Kittiwan Choojitarom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Orawan Verasertniyom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kitti Totemchokchyakarn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kanokrat Nantiruj
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vasant Sumethkul
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Suchela Janwityanujit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suchela Janwityanujit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choojitarom, K., Verasertniyom, O., Totemchokchyakarn, K. et al. Lupus nephritis and Raynaud’s phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clin Rheumatol 27, 345–351 (2008). https://doi.org/10.1007/s10067-007-0721-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-007-0721-z

Keywords

Search

Navigation